ÌÚ²©»á¹ÙÍø


TEL:17312606166£¨É¡Ë¾Àí£©

VRͼ±ê°×É« VRͼ±êÐþÉ«
X

ÌÚ²©»á¹ÙÍøÁÙ´²Ç°´ó¶¯ÎïʵÑéÖÐÐÄ

ÓëÎÒÃÇÈ¡µÃÁªÏµ

    17312606166

GLP-1RØ­2ÐÍÌÇÄò²¡ÖÎÁƵÄÃ÷Ðǰеã

ÄúµÄλÖãºÊ×Ò³ >> ÐÐÒµ¶¯Ì¬ >> ×ÊѶ

È«Çò¸ß´ï4ÒÚ¶àÈ˱¥ÊÜÌÇÄò²¡À§ÈÅ £¬ÆäÖÐÎÒ¹úÌÇÄò²¡»¼²¡ÈËÊý¾ÓÈ«ÇòÖ®Ê× £¬Òѳ¬1.3 ÒÚ £¬Õ¼ÌìÏÂ×ÜÉú³ÝµÄ 9.4%[1]¡£ÒȸßѪÌÇËØÑùëÄ-1ÊÜÌ壨glucagon-like peptide-1 receptor, GLP-1R£©ÊÇÖÎÁÆ2ÐÍÌÇÄò²¡×îÓÐÓõİеãÖ®Ò»¡£

image.png

ͼ1 È«ÇòÌÇÄò²¡»¼Õßͳ¼Æ

×òÈÕ£¨8ÔÂ18ÈÕ£©ÐÅ´ïÉúÎïµÄÐÂÐÍGLP-1R/GCGRË«¼¤¶¯¼ÁIBI362 (LY3305677)Ò»ÆÚÁÙ´²Ð§¹ûÔÚ¹ú¼Ê×ÅÃûÆÚ¿¯ÁøÒ¶µ¶×Ó¿¯EClinicalMedicineÉϽÒÏþ¡£½ñÄê4Ô £¬ÅµºÍŵµÂµÄGLP-1R¼¤¶¯¼Á¶àëÄ˾ÃÀ¸ñ³ëÄ×¢ÉäÒºÔÚº£ÄÚÉÏÊÐ £¬Ã¿ÖÜÖ»ÐèƤÏÂ×¢Éä1´Î¡£ÏÖÔÚº£ÄÚÉÏÊеÄGLP-1R¼¤¶¯¼ÁÀàÒ©ÎïµÖ´ï8¿î £¬ËüÃDz»µ«½µÌÇЧ¹ûÏÔÖø £¬Í¬Ê±»¹¼æ¾ß¼õÖØ¡¢½µÑ¹¡¢¸ÄÉÆѪ֬Æ×µÈ×÷Ó᣽üÄêÀ´GLP-1R¼¤¶¯¼ÁÀàÒ©ÎïÊг¡¹æÄ£Ò»Ö±ÔöÌí £¬2020ÄêÈ«ÇòÊг¡¹æÄ£ÒÑ´ï100ÒÚÃÀÔª¡£

GLP-1RΪºÎÄÜÔÚ2ÐÍÌÇÄò²¡ÖÎÁÆÉÏ´ó·ÅÒì²Ê £¬½ñÌìС±à´ø¸÷ÈËһ̽ÊÂʵ¡£

GLP-1R¼ò½é

GLP-1RÊôÓÚGÂÑ°×żÁªÊÜÌåB´ØÖÐÒȸßѪÌÇËØÊÜÌåÑǼÒ×å £¬ËüµÄµä·¶ÌØÕ÷ÊǾßÓÐÒ»¸öÆߴοçĤµÄ½¹µãÓòºÍÒ»¸öÏà¶Ô½ÏÁ¿´óµÄ°ûÍâÓò[2]¡£È˵ÄGLP-1R»ùÒòλÓÚµÚ6ºÅȾɫÌåÉÏ £¬±àÂë463¸ö°±»ùËá¡£ÒÈÏÙÄÚµÄGLP-1RÖ÷Òª±í´ïÔÚÒȵº¦Âϸ°ûÖÐ £¬³ýÒȵºÍâ £¬GLP-1R»¹ÆÕ±é±í´ïÓÚθ¡¢Ð¡³¦¡¢ÐÄÔà¡¢ÉöÔà¡¢·Î¼°´óÄÔµÈ×éÖ¯Æ÷¹ÙÖÐ[3]¡£¹ËÃû˼Òå £¬GLP-1RµÄÖ÷Òª×÷ÓÃÊǺÍÒȸßѪÌÇËØÑùëÄ-1£¨glucagon-like peptide-1 receptor, GLP-1£©ÍŽá £¬µ÷ÀíѪÌÇ¡£

image.png

ͼ2 GLP-1R¿çĤÇøÈýά½á¹¹

GLP-1

GLP-1ÊÇÒ»ÖÖÖ÷ÒªÓɳ¦µÀLϸ°ûËù±¬·¢µÄ¼¤ËØ £¬ÊôÓÚ³¦´ÙÒÈËØ¡£GLP-1µÄ°ëË¥ÆÚºÜÊǶÌ £¬½ö1-2min £¬ÆäÊ©Õ¹ÐÄÀí¹¦Ð§Ö÷ÒªÊÇͨ¹ýÍŽᲢ¼¤»îGLP-1R¡£ÈËÌåÄÚ³¦´ÙÒÈËسýGLP-1ÍâÉÐÓÐÆÏÌÑÌÇÒÀÀµÐÔÒȵºËØÊÍ·ÅëÄ£¨GIP£© £¬¿ÉÊÇÖ»ÓÐGLP-1¿ÉÒÔÒÖÖÆÒȸßѪÌÇËصÄÊÍ·Å £¬ÒýÆð±¥×ã¸Ð[4]¡£×èÖ¹µ½2021Äê £¬ÁÙ´²Éϳ¦´ÙÒÈËØÀàÒ©Îï¾ù»ùÓÚGLP-1¡£

GLP-1RµÄ¹¦Ð§

GLP-1RÆÕ±éÂþÑÜÔÚÒȵº¡¢Î¸¡¢Ð¡³¦¡¢ÐÄÔà¡¢ÉöÔà¡¢·Î¡¢´óÄÔµÈ×éÖ¯Æ÷¹ÙÖÐ £¬µ±Ëü±»GLP-1ijÈ˹¤ºÏ³ÉµÄGLP-1R¼¤¶¯¼Á¼¤»îºó £¬±ãÄÜÊ©Õ¹¶àÖÖ²î±ðµÄÐÄÀí¹¦Ð§¡£ÔÚÒȵºÏ¸°ûÖÐ £¬GLP-1RµÄÖ÷Òª×÷ÓÃÊÇÔö½øÒȵº¦Âϸ°ûµÄÔöÖ³ £¬´Ì¼¤ÒȵºËصĺϳÉÓëÊÍ·Å £¬²¢ÒÖÖÆÒȸßѪÌÇËصĺϳÉÓëÊÍ·Å¡£ÔÚ賦µÀµÈ×éÖ¯ÖÐ £¬GLP-1R¿ÉÒÔÒÖÖÆθҺÉø͸ºÍ賦µÀµÄÈ䶯 £¬ÑÓ³ÙθµÄÅÅ¿Õ £¬ÔöÌí÷ÐâÀ¸Ð £¬ïÔ̭ʳÎïÉãÈ¡[4]¡£ÔÚÉñ¾­×éÖ¯ÖÐ £¬GLP-1R¿ÉÒÔ±£»¤Éñ¾­Ï¸°û £¬¶Ô¿¹Ê³Óû²»Õñ £¬ÔöÇ¿Ó°ÏóÁ¦¡£ÔÚÐÄѪ¹Ü·½Ãæ £¬GLP-1R¿ÉÒÔÌáÉýÐÄѪ¹ÜµÄ¹¦Ð§ £¬ïÔÌ­Ñ×Ö¢[5]¡£

image.png

ͼ3  GLP-1RµÄÐÄÀí¹¦Ð§

GLP-1RµÄ¼¤»î

GLP-1RÓëÅäÌåµÄÍŽ᷽·¨Ö÷ÒªÊǸ÷ÈËÊìÖªµÄ¡°two-domain model¡±¡£ÅäÌåµÄC¶ËÏÈͬGLP-1RµÄ°ûÍâÓòÍŽá £¬Ê¹GLP-1RµÄ¿Õ¼ä¹¹Ï󱬷¢¸Ä±ä £¬Ì»Â¶³ö½¹µãÓòµÄÍŽáλµã £¬È»ºóÅäÌåµÄN¶ËͬGLP-1RµÄ½¹µãÓòÍŽá £¬¼¤»îGLP-1R¡£Ò»Ñùƽ³£À´Ëµ £¬GLP-1R°ûÍâÓòµÄÖ÷Òª×÷ÓÃÊÇʶ±ðÌØÒìÐÔµÄÅäÌå £¬¶ø½¹µãÓòÔòÔÚÐźÅÌØÒìÐÔ´«µ¼ÖÐÊ©Õ¹Ö÷Òª×÷ÓÃ[6]¡£

image.png

ͼ4 GLP-1RÓëÅäÌåÍŽáµÄģʽͼ

GLP-1RÐźÅתµ¼µ÷¿Ø»úÖÆ

GLP-1RÊÇÒ»ÖÖ¶àЧÐÔżÁªÊÜÌå £¬Ö÷Ҫͨ¹ýÓë¶àÖÖGÂÑ°×£¨G¦Ás¡¢G¦Ái¡¢G¦ÁoºÍG¦Áq/11£©Å¼ÁªÀ´µ÷¿Øϸ°ûͨ·¡£µ±ÓëGLP-1ÍŽáºó £¬GLP-1RÔÚÒȵº¦Âϸ°ûÖÐżÁªG¦ÁsÂÑ°× £¬¼¤»îÏÙÜÕ»·»¯Ã¸ £¬´ÙʹcAMPÔÚϸ°ûÄÚº¬Á¿Éý¸ß £¬ÒýÆð¸ÆÀë×ÓÄÚÁ÷ £¬ÒȵºËØÔ­»ùÒòת¼ÔöÌí £¬´Ì¼¤ÑªÌÇÒÀÀµÐÔÒȵºËصÄÉø͸[7]¡£³ý´ËÖ®Íâ £¬GLP-1R»¹¿ÉÒÔͨ¹ý¼¤»îPI3K¡¢MAPKºÍRas/MAPKÐźÅͨ·À´Ôö½øÒȵº¦Âϸ°ûµÄÔöÖ³ºÍ·Ö½â¡£²»µ«ÔÆÔÆ £¬GLP-1R»¹Äܹ»Í¨¹ýµ÷¿ØcAMP·´Ó¦Ôª¼þÍŽáÂÑ°×£¨CREB£©ºÍÂѰ׸´ÉúÒò×ÓBcl-2¡¢Bcl-XLµÈÀ´ÒÖÖÆϸ°ûµòÍö[8]¡£

image.png

ͼ5 Òȵº¦Âϸ°ûÖÐGLP-1Rµ÷¿ØµÄÐźÅͨ·

С·Ö×Ó·ÇëÄÀàGLP-1R¼¤¶¯¼Á

2019ÄêŵºÍŵµÂÐû²¼FDAÅú×¼Æä¿Ú·þË÷Âí³ëÄ£¨ÉÌÆ·ÃûRybelsus£©ÉÏÊÐ £¬³ÉΪȫÇòÊ׿î¿Ú·þGLP-1R¼¤¶¯¼Á¡£¿Ú·þË÷Âí³ëĵķºÆðÍ»ÆÆÁËÌÇÄò²¡»¼ÕßÐèÒªÌìÌì»òÿÖÜ×¢ÉäÒ©ÎïµÄÏÖ×´ £¬±¸ÊÜÊг¡¹Ø×¢ £¬ÏÆÆðÁËС·Ö×Ó·ÇëÄÀàGLP-1R¼¤¶¯¼ÁÒ©ÎïµÄÑз¢Å­³±£¡

image.png

±í1 ÔÚÑÐС·Ö×ÓGLP-1R¼¤¶¯¼Á

GLP-1RÈËÔ´»¯Ð¡Êó

¼øÓÚGLP-1RÔÚ2ÐÍÌÇÄò²¡Ò©Î↑·¢ÖеÄÖ÷Òª×÷Óà £¬ÉϺ£ÄÏ·½Ä£Ê½ÉúÎï¿Æ¼¼¹É·ÝÓÐÏÞ¹«Ë¾£¨Shanghai Model Organisms Center £¬Inc. £¬¼ò³Æ¡°ÄÏÄ£ÉúÎ£©×ÔÖ÷Ñз¢ÁËGLP-1RÈËÔ´»¯Ð¡ÊóÄ£×Ó £¬ÎªÌÇÄò²¡Ò©Îïɸѡ £¬Ïà¹ØҩЧʵÑéµÈÑо¿ÌṩÁËÇ¿ÓÐÁ¦µÄ¹¤¾ß¡£

½µÑªÌÇҩЧÑéÖ¤

GLP-1RÈËÔ´»¯Ð¡Êó £¬ÔÚ¸øÒ©ºÍ²»¸øÒ©µÄÌõ¼þϾÙÐпڷþÌÇÄÍÁ¿£¨OGTT£©ÊµÑ飨n=5£©¡£

image.png

ͼ6 OGTTʵÑ飨ÑéÖ¤Êý¾ÝÓÉ¿Í»§Ìṩ£©

Ч¹ûÏÔʾ£ºÕë¶ÔÈËÔ´GLP-1R £¬´ý²â»¯ºÏÎïÌåÏÖ³öºÜºÃµÄ½µÑªÌÇЧ¹û£¨p<0.001£©¡£ÉÏÊöÊý¾Ý֤ʵ £¬GLP-1RÈËÔ´»¯Ð¡ÊóÄ£×Ó £¬ÊǾÙÐÐÌÇÄò²¡Ò©ÎïɸѡµÄÓÐÓù¤¾ß¡£

ÄÏÄ£ÉúÎïÉî¸û»ùÒò±à¼­ÁìÓò £¬Ìṩȫ·½Î»Ä£Ê½ÉúÎïЧÀÍ £¬°üÀ¨»ùÒòÐÞÊÎÖÆÆ·Ä£×Ó¹©Ó¦¡¢¸öÐÔ»¯Ä£×Ó¶¨ÖÆ¡¢ËÇÑø·±Óý¡¢±íÐÍÆÊÎö¡¢Ò©Ð§ÆÀ¼ÛµÈ £¬Öª×ã²î±ðʵÑéÊÒÐèÇó¡£

Reference:

[1]¹ú¼ÊÌÇÄò²¡Í¬ÃË IDF 2019È«ÇòÌÇÄò²¡µØͼ(µÚ9°æ)

[2]Blad CC, Tang C, Offermanns S. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nature Reviews Drug Discovery, 2012, 11 : 603¨C619. 

[3]Pabreja K, Mohd MA, Koole C, et al. Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. British Journal of Pharmacology, 2014, 171 : 1114¨C1128. DOI:10.1111/bph.12313

[4]Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors & Channels, 2011, 8 : 179¨C188.

[5]Laviola L, Leonardini A, Melchiorre M, et al. Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology, 2012, 153 : 5770¨C5781. DOI:10.1210/en.2012-1461

[6]ºúÖÐƽ, ³ÌÄî, Ñî·«, ËÕÕý¶¨. GLP-1R½á¹¹ºÍ¹¦Ð§¼°Ð¡·Ö×ÓÒ©ÎïɸѡÑо¿Ï£Íû[J]. ÉúÎïÊÖÒÕת´ï, 2017, 33(2): 30-40

[7]Dalle S, Ravier MA, Bertrand G. Emerging roles for ¦Â-arrestin-1 in the control of the pancreatic ¦Â-cell function and mass: New therapeutic strategies and consequences for drug screening. Cellular Signalling, 2011, 23 : 522¨C528. DOI:10.1016/j.cellsig.2010.09.014

[8]Robert G, Xiaomang Y, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology, 2003, 144 : 2242¨C2252. DOI:10.1210/en.2003-0007

ÉÏһƪ£º½ôËæÖ¸ÄÏ¡ªÄÔ¿ÆѧÑо¿¶¯ÎïÄ£×Ó»ã×Ü ÏÂһƪ£ºÑо¿·¢Ã÷£ºËÜÁϽµ½â¿ÅÁ£»òΪ¾«Éñ¼²²¡Ç±ÔÚ·¢²¡Ôµ¹ÊÔ­ÓÉ

Ïà¹ØÔĶÁ ¸ü¶à>>

²ÂÄúϲ»¶¸ü¶à>>

¶¯ÎïÊÔÑé

ÁÙ´²Åàѵ

Ä¥Á·¼°²¡Àí

ÁÙ´²ÊÔÑé

²úÆ·×¢²á

 

ÌìÏÂÃâ·Ñ×Éѯ:

ÓªÒµ×Éѯ£º17312606166£¨É¡Ë¾Àí£©

½Ú¼ÙÖµ°à£º17312606166£¨Î¢Ðźţ©

ÁªÏµµØµã£º
ËÕÖÝ£ºËÕÖÝÊÐËÕÖݹ¤ÒµÔ°ÇøʤÆÖ½ÖµÀÐËÆÖ·200ºÅ
Ì©ÖÝ£º½­ËÕÊ¡Ì©ÖÝÊÐÒ½Ò©¸ßÐÂÇøÐãˮ·20ºÅ19´±
¹ãÖÝ£º¹ãÖÝÊÐÀóÍåÇø»¨µØ´óµÀÖÐ228ºÅ

Copyright © 2018-2024 ÌÚ²©»á¹ÙÍø      ICP±¸°¸£ºËÕICP±¸17068211ºÅ Ö§³Öµ¥Î»£ºÌÚ²©»á¹ÙÍø

ÔÚÏß
¿Í·þ

ÊÖÒÕÔÚÏßЧÀÍʱ¼ä£º9:00-20:00

ÔÚÌÚ²©»á¹ÙÍø £¬Äú¶Ô½ÓµÄÊÇÊÖÒÕÖ°Ô± £¬¶ø·Ç¿Í·þ´«»°£¡

  • ´ó¶¯ÎïÊÔÑé
  • ÁÙ´²Åàѵ
  • ×éÖ¯²¡Àí
  • ÁÙ´²ÊÔÑé
  • ²úÆ·×¢²á
  • ¿ÆÑпÎÌâ

µç»°
×Éѯ


7*24Сʱ¿Í·þÈÈÏß

17312606166
ÏîĿ˾ÀíÊÖ»ú

΢ÐÅ
×Éѯ

¼Ó΢ÐÅ»ñÈ¡¶Ô½Ó
¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿